# Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

> **NCT04947319** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Refractory Primary Central Nervous System Lymphoma
- Primary CNS Lymphoma

## Interventions

- **DRUG:** Tirabrutinib
- **DRUG:** Tirabrutinib
- **DRUG:** Tirabrutinib

## Key facts

- **NCT ID:** NCT04947319
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-29
- **Primary completion:** 2026-01-27
- **Final completion:** 2027-03-31
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04947319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04947319, "Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04947319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*